Parkinsonism and exposure to neuroleptic drugs in elderly people living in institutions

Clinical Neuropharmacology

Volumn 22, Issue 1, 1999, Pages 5-10

  Tison, François ^a   Lecaroz, Jean ^a   Letenneur, Luc ^b   Dartigues, Jean François ^b  

^a HÔPITAL PELLEGRIN   (France)

^b INSERM   (France)

Author keywords

Elderly; Institutions; Neuroleptic induced parkinsonism

Indexed keywords

NEUROLEPTIC AGENT;

AGED; ARTICLE; COGNITION; DEMENTIA; ELDERLY CARE; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN TISSUE; INSTITUTIONALIZATION; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; PRIORITY JOURNAL; SCORING SYSTEM; TREMOR;

EID: 0032928487     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199901000-00002     Document Type: Article

References (19)

1. Svarstad BL, Mount JK. Nursing home resources and tranquilizer use among the institutionalized elderly. JAm Geriatr Soc 1991;39: 869-875.
2. Mc Grath AM, Jackson GA. Survey of neuroleptic prescribing in residents of nursing homes in Glasgow. BMJ 1996;312:611-612.
3. Avorn J, Monane M, Everitt DE, Beers MH, Fields D. Clinical assessment of extrapyramidal signs in nursing home patients given antipsychotic medication. Arch Intern Med 1994;154:1113-1117.
4. Stephen PJ, Williamson J. Drug-induced parkinsonism in the elderly. Lancet 1984;332:1082-1083.
5. Mc Shane R, Keene J, Gedling K, Faiburn C, Jacoby R, Hope T. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow-up. BMJ 1997;314:266-270.
6. Tison F, Dartigues JF, Dubes L, Zuber M, Alpérovitch A, Henry P. Prevalence of Parkinson's disease in the elderly: a population study in Gironde, France. Acta Neurol Scand 1994;90:111-115.
7. Larsen JP and the Norwegian Study Group of Parkinson's Disease in the elderly. Parkinson's disease as community health problem: study in Norwegian nursing homes. BMJ 1991;303:741-743.
8. Moghal S, Rajput AH, Meleth R, D'Arcy C, Rajput R. Prevalence of movement disorders in institutionalized elderly. Neuroepidemiology 1995;14:297-300.
9. Dartigues JF, Gagnon M, Barberger-Gateau P, et al. The Paquid epidemiological program on brain aging. Neuroepidemiology 1992; 11(suppl 1):14-18.
10. Tison F, Dartigues JF, Auriacombe S, Letenneur L, Boller F, Alpérovitch A. Dementia in Parkinson's disease: a population-based study in ambulatory and institutionalized individuals. Neurology 1995;45:705-708.
11. Baldessarini RJ, Katz B, Cotton P. Dissimilar dosing with high-potency and low-potency neuroleptics. Am J Psychiatry 1984;141: 748-752.
12. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol 1969;21:343-354.
13. Montastruc JL, Llau ME, Rascol O, Senard JM. Drug-induced parkinsonism: a review. Fundam Clin Pharmacol 1994;8:293-306.
14. Ayd FJ Jr. A survey of drug-induced extrapyramidal reactions. JAMA 1961;175:1054-1060.
15. Tarsy D. Neuroleptic, induced extrapyramidal reactions: classification, description and diagnosis. Clin Neuropharmacol 1983;6(suppl 1):9-26.
16. Beers M, Avorn J, Soumerai SB, Everitt DE, Sherman DS, Salem S. Psychoactive medication use in intermediate-care facility residents. JAMA 1988;260:3016-3020.
17. Ray WA, Federspiel CF, Schaffner W. A study of antipsychotic drug use in nursing homes: epidemiologic evidence suggesting misuse. Am J Public Health 1980;70:85-91.
18. Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 1988;51:850-854.
19. Avorn J, Bohn RL, Mogun H, et al. Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study. Am J Med 1995;99:48-54.